Closed-loop insulin delivery in inpatients with type 2 diabetes: a randomised, parallel-group trial

Publication date: Available online 9 November 2016 Source:The Lancet Diabetes & Endocrinology Author(s): Hood Thabit, Sara Hartnell, Janet M Allen, Andrea Lake, Malgorzata E Wilinska, Yue Ruan, Mark L Evans, Anthony P Coll, Roman Hovorka Background We assessed whether fully closed-loop insulin delivery (the so-called artificial pancreas) is safe and effective compared with standard subcutaneous insulin therapy in patients with type 2 diabetes in the general ward. Methods For this single-centre, open-label, parallel-group, randomised controlled trial, we enrolled patients aged 18 years or older with type 2 diabetes who were receiving insulin therapy. Patients were recruited from general wards at Addenbrooke’s Hospital, Cambridge, UK. Participants were randomly assigned (1:1) by a computer-generated minimisation method to receive closed-loop insulin delivery (using a model-predictive control algorithm to direct subcutaneous delivery of rapid-acting insulin analogue without meal-time insulin boluses) or conventional subcutaneous insulin delivery according to local clinical guidelines. The primary outcome was time spent in the target glucose concentration range of 5·6–10·0 mmol/L during the 72 h study period. Analyses were by intention to treat. This trial is registered with ClinicalTrials.gov, number NCT01774565. Findings Between Feb 20, 2015, and March 24, 2016, we enrolled 40 participants, of whom 20 were randomly assigned to the closed-loop interven...
Source: The Lancet Diabetes and Endocrinology - Category: Endocrinology Source Type: research